Glibornuride

Glibornuride Overview

Glibornuride is an organic bicyclic monoterpenoid derivative and second-generation sulfonylurea oral anti-diabetic drug. Chemically, it belongs to the class of bicyclic monoterpenoids under the prenol lipids superclass. Structurally, it combines an endo-hydroxybornyl bicyclic ring framework with a toluenesulfonylurea core.

In clinical endocrinology and metabolic pharmacology, Glibornuride is utilized as an oral blood glucose-lowering agent for the management of non-insulin-dependent type 2 diabetes mellitus. Marketed internationally under brand names such as Glutril (Meda Pharma), Glibornuride stimulates endogenous insulin secretion from pancreatic beta-cells to restore glycemic control in patients whose blood sugar levels are inadequately managed by diet and lifestyle modifications alone. It is metabolized predominantly by Cytochrome P450 CYP2C9 enzymes.

What Is Glibornuride and How Does It Work?

Glibornuride is a small molecule sulfonylurea derivative that acts as an insulin secretagogue.

Its primary physiological and intracellular mechanisms include:

• ATP-Sensitive Potassium Channel Blockade: Glibornuride binds selectively to sulfonylurea receptors (SUR1 subunits) associated with ATP-sensitive potassium () channels on the plasma membranes of pancreatic beta-cells.
• Depolarization & Calcium Influx: Inhibition of  channels halts potassium efflux, leading to membrane depolarization. Depolarization opens voltage-gated calcium channels, inducing an influx of extracellular calcium into pancreatic beta-cells.
• Stimulation of Endogenous Insulin Release: Increased intracellular calcium concentration triggers exocytosis of pre-formed insulin granules, promoting glucose-dependent and basal insulin secretion into the bloodstream.
• Metabolic Clearance: Glibornuride is metabolized in the liver primarily via Cytochrome P450 CYP2C9 enzymes into inactive metabolites that are excreted renally and fecally.

Is Glibornuride FDA Approved?

No, Glibornuride is not approved by the US FDA for commercial distribution or clinical prescription in the United States. However, it is an established, approved second-generation sulfonylurea oral hypoglycemic agent across various European and international jurisdictions, having been first approved in Europe in 1972 under the trade name Glutril. Internationally, endocrinologists prescribe Glibornuride for the management of non-insulin-dependent type 2 diabetes mellitus when diet and lifestyle modifications alone fail to achieve adequate glycemic control.

What Is Glibornuride Used For?

• Management of type 2 diabetes mellitus in adult patients as an adjunct to diet and exercise to improve glycemic control.
• Second-line oral hypoglycemic therapy in patients with non-insulin-dependent diabetes who fail to achieve adequate glycemic control with lifestyle interventions or metformin monotherapy.

Before Taking Glibornuride: Contraindications & Precautions

Strictly contraindicated in individuals with type 1 diabetes mellitus, diabetic ketoacidosis, or a documented hypersensitivity to Glibornuride, sulfonylureas, or sulfonamides. Do not use in patients with severe renal or severe hepatic impairment, as decreased metabolic clearance drastically elevates the risk of severe, prolonged hypoglycemia. Not recommended during severe systemic infections, trauma, major surgery, or pregnancy and lactation; patients requiring blood glucose control during gestation or acute stress should be transitioned to insulin therapy.

Who Should Not Take Glibornuride?

• Individuals with a documented hypersensitivity to Glibornuride, sulfonylureas, sulfonamides, or formulation excipients.
• Patients with type 1 diabetes mellitus or diabetic ketoacidosis.
• Individuals with severe renal or severe hepatic impairment, as drug clearance is reduced, elevating the risk of severe, prolonged hypoglycemia.
• Patients experiencing severe trauma, major surgery, or severe systemic infections where insulin therapy is required.

Glibornuride, Pregnancy & Fertility

Systemic drug exposure occurs readily following oral administration. Sulfonylurea drugs cross the placenta and can induce prolonged, severe hypoglycemia in newborns. Adequate and well-controlled clinical trials in pregnant women are lacking. Glibornuride is strictly non-recommended during pregnancy and breastfeeding; patients should be transitioned to insulin therapy during gestation.

Tell Your Doctor Before Taking Glibornuride

Inform your endocrinologist or physician if you have a history of glucose-6-phosphate dehydrogenase (G6PD) deficiency, mild-to-moderate renal or hepatic dysfunction, adrenal or pituitary insufficiency, or severe thyroid disease. Disclose all prescription drugs you take, particularly CYP2C9 inhibitors or inducers.

Glibornuride Dosage & Administration

Formulated as oral tablets. Glibornuride (Glutril) is an approved second-generation sulfonylurea in various European and international jurisdictions, though it is not approved by the US FDA. Standard starting oral doses typically range from 12.5 mg to 25 mg taken once daily with or immediately before breakfast. Depending on glycemic response and HbA1c, the dosage may be titrated up to a maximum of 75 mg daily (divided into 2 doses with main meals). Take immediately before main meals and never skip meals following administration.

Standard Glibornuride Dosing

• Type 2 Diabetes Mellitus (Oral Tablets): Standard starting therapeutic dosages typically range from 12.5 mg to 25 mg taken orally once daily with breakfast.
• Depending on blood glucose measurements and HbA1c response, the daily dosage may be titrated up to a maximum recommended dose of 75 mg daily (divided into 2 doses taken with main meals).

How Glibornuride Is Administered

• Administered via the oral route in tablet form.
• Take tablets immediately before or during breakfast or the first main meal of the day to reduce the risk of hypoglycemia.
• Do not skip meals after taking a dose.

Glibornuride Clinical Efficacy & Research

Clinical trials demonstrate that Glibornuride is an effective second-generation sulfonylurea, producing clinically significant reductions in fasting plasma glucose, postprandial blood sugar, and HbA1c levels in adult patients with type 2 diabetes. Clinical studies confirm that its sulfonylurea receptor affinity yields rapid beta-cell response with a predictable duration of action, maintaining sustained glycemic control when combined with appropriate dietary management.

Glibornuride Side Effects & Safety Profile

Common adverse reactions include hypoglycemia (sweating, tremors, dizziness, hunger, tachycardia), mild gastrointestinal distress (nausea, heartburn, constipation), moderate weight gain, and headache. Serious adverse risks include severe, life-threatening prolonged hypoglycemia, cholestatic jaundice, elevated liver enzymes, hematologic toxicity (leukopenia, agranulocytosis, thrombocytopenia, hemolytic anemia in G6PD deficiency), and severe cutaneous hypersensitivity (Stevens-Johnson syndrome). Holds no US FDA Black Box Warning due to its unapproved status in North America.

Common Glibornuride Side Effects

• Hypoglycemia (low blood sugar), presenting with sweating, shakiness, dizziness, hunger, and tachycardia.
• Mild gastrointestinal disturbances, including nausea, heartburn, abdominal fullness, or constipation.
• Moderate weight gain secondary to enhanced endogenous insulin secretion.
• Transient headache or lightheadedness.

Serious Glibornuride Adverse Events

• Severe Hypoglycemia: Profound drops in blood glucose leading to confusion, seizures, loss of consciousness, coma, or fatal outcomes.
• Hepatotoxicity: Rare cholestatic jaundice, elevated hepatic transaminases, or hepatitis.
• Hematologic Disorders: Rare leukopenia, thrombocytopenia, agranulocytosis, or hemolytic anemia (particularly in G6PD deficiency).
• Cutaneous Hypersensitivity: Severe allergic skin reactions, pruritus, erythema, or Stevens-Johnson syndrome.

Managing Glibornuride Side Effects

Mild hypoglycemic episodes should be treated immediately by consuming fast-acting oral carbohydrates (such as glucose tablets or fruit juice). If severe hypoglycemia or loss of consciousness occurs, seek immediate emergency medical care for intravenous dextrose or glucagon administration.

Glibornuride Drug Interactions & What to Avoid

Metabolized primarily by CYP2C9; co-administration with CYP2C9 inhibitors (e.g., fluconazole, miconazole, amiodarone) decreases drug clearance and severely elevates hypoglycemia risks. Beta-blockers and ACE inhibitors potentiate hypoglycemic effects, with non-selective beta-blockers masking autonomic warning signs (tachycardia, tremors). Thiazide diuretics and corticosteroids antagonize hypoglycemic actions, elevating blood glucose. Avoid alcohol, as it impairs hepatic gluconeogenesis and precipitates severe, unpredictable hypoglycemia or disulfiram-like flushing reactions.

Glibornuride Drug-Drug Interactions

• CYP2C9 Inhibitors (e.g., Fluconazole, Miconazole, Amiodarone): Inhibit Glibornuride clearance, markedly increasing plasma levels and elevating hypoglycemia risks.
• Beta-Blockers & ACE Inhibitors: May potentiate hypoglycemic effects; non-selective beta-blockers can mask autonomic warning signs of hypoglycemia (such as tachycardia and tremors).
• Thiazide Diuretics & Corticosteroids: Antagonize hypoglycemic actions, leading to elevated blood glucose levels.

Glibornuride, Food & Alcohol

Avoid alcohol consumption during treatment. Alcohol impairs hepatic gluconeogenesis and can precipitate severe, unpredictable, and prolonged hypoglycemia (or induce disulfiram-like flushing reactions).

Glibornuride: Missed Dose, Overdose & Storage

If a dose is missed, take it with the next main meal on that day; if near the next scheduled dose, skip the missed dose and resume the normal routine without taking extra tablets. Overdose causes severe, prolonged hypoglycemia, seizures, and coma, requiring immediate emergency medical care and continuous intravenous infusion of hypertonic dextrose solutions. Store tablets at controlled room temperature (15°C–30°C) protected from excessive heat, moisture, and direct light.

Missed Dose of Glibornuride

If a dose is missed, take it with your next main meal on that day. If it is almost time for the next meal or scheduled dose, skip the missed dose and resume your regular daily schedule. Do not take extra tablets to make up for a missed dose.

Glibornuride Overdose & Emergency

Overdose of Glibornuride causes severe, life-threatening hypoglycemia, prolonged neurological impairment, and coma. Seek immediate emergency medical care; management requires continuous glucose monitoring and prolonged intravenous infusion of hypertonic dextrose solutions.

How to Store Glibornuride

Store oral tablets at controlled room temperature between 15°C and 30°C (59°F to 86°F). Protect from excessive heat, moisture, and direct light. Keep strictly out of reach of children.

Glibornuride Patient Management & Monitoring

Obtain baseline fasting plasma glucose, postprandial glucose, HbA1c, liver function tests (ALT, AST, total bilirubin), and renal function panels (serum creatinine, eGFR) prior to initiating therapy; screen for G6PD deficiency if clinically indicated. Regularly perform self-monitoring of blood glucose (SMBG) and measure HbA1c every 3 to 6 months. Routinely evaluate renal and hepatic function, and monitor closely for signs of low blood sugar.

Tests Before Starting Glibornuride

• Baseline fasting plasma glucose, postprandial glucose, and HbA1c levels.
• Baseline liver function tests (ALT, AST, total bilirubin) and renal function panels (serum creatinine, eGFR).
• Screening for G6PD deficiency if clinically indicated.

Monitoring During Glibornuride Treatment

Routine self-monitoring of blood glucose (SMBG) and periodic laboratory HbA1c testing every 3 to 6 months. Regularly evaluate renal and hepatic function.

Glibornuride Do’s and Don’ts

• Do take your dose with or immediately before a meal.
• Do carry fast-acting carbohydrates (such as glucose tablets) at all times to manage low blood sugar.
• Do not skip meals after taking your medication.
• Do not consume alcohol while taking Glibornuride.

Frequently Asked Questions

References

• DrugBank Database – Glibornuride Clinical and Pharmacological Profile (DB08962)
• Classyfire Database – Bicyclic Monoterpenoids Chemical Taxonomy Profile

Legal Disclaimer

The detailed medical and chemical information provided on this specific web page is intended strictly for educational and informational purposes regarding complex pharmacological mechanisms. It absolutely does not constitute professional medical advice, medical diagnosis, or specific treatment recommendations. Always consult a licensed healthcare provider before making any personal decisions regarding complex cardiovascular conditions, medication adjustments, or dietary changes.